A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
Latest Information Update: 26 Nov 2023
At a glance
- Drugs LY 3526318 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Acronyms CPMP
- Sponsors Eli Lilly and Company
Most Recent Events
- 21 Nov 2022 Status changed from recruiting to completed.
- 22 Jun 2022 Planned End Date changed from 19 Sep 2022 to 24 Nov 2022.
- 22 Jun 2022 Planned primary completion date changed from 19 Sep 2022 to 24 Nov 2022.